News
9d
SurvivorNet on MSNNew Hope for Patients With Advanced Lung Cancer: Datroway, A New FDA ApprovalA new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...
The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a Phase 2 trial. The approval was also supported by data from a Phase 3 trial ...
The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.
AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...
Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.
Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.
During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results